内容摘要：Associated Press reporter Holly Ramer in Concord, New Hampshire, contributed.

Associated Press reporter Holly Ramer in Concord, New Hampshire, contributed.

But that standard appears to be shifting. FDA staffers were poised to approveearly last month but the decision was delayed by administration officials, including Makary, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss agency matters. The shot was approved late Friday with unusual restrictions.

Dr. Tracy Beth Hoeg — a political appointee serving as Makary’s special assistant — was involved in the unprecedented demand that Novavax conduct a new clinical trial of its shot after approval, according to the people. The requirement came shortly after the agency’s longtime vaccine chief,, was forced to resign.Hoeg — along with Makary and Prasad — spent much of the COVID-19 pandemic criticizing the FDA’s handling of booster shots, particularly in children and young adults. All three were co-authors of a 2022 paper stating that requiring booster shots in young people would cause more harm than benefit.

Novavax isn’t the only vaccine manufacturer already affected by changing attitudes at FDA. Earlier this month, Moderna pushed back the target date for its new COVID-and-flu combination vaccine to next year after the FDA requested additional effectiveness data.As the FDA’s top official overseeing vaccines, Prasad is now in position to reverse what he recently called “a number of missteps” in how the FDA assessed the benefits and risks of COVID-19 boosters.

He questioned how much benefit yearly vaccinations continue to offer. In a podcast shortly before assuming his FDA job, Prasad suggested companies could study about 20,000 older adults in August or September to show if an updated vaccine prevented COVID-related hospitalizations.

There is “legitimate debate about who should be boosted, how frequently they should be boosted and the value of boosting low-risk individuals,” said Hopkins’ Adalja. But he stressed that CDC’s Advisory Committee on Immunization Practices has the proper expertise to be making those decisions.According to Montero, the myth implies that, after a god’s passing, its essence gets imprisoned in a mundane creature, subject to the cycles of life and death. Axolotl then carries within itself the Xolotl deity, and when the animal dies and its divine substance transits to the underworld, it later resurfaces to the earth and a new axolotl is born.

“Axolotl is the twin of maize, agave and water,” Montero said.Current fascination toward axolotl and its rise to sacred status in pre-Hispanic times is hardly a coincidence. It was most likely sparked by its exceptional biological features, Montero said.

Through the glass of a fish tank, where academic institutions preserve them and hatcheries put them up for sale, axolotl are hard to spot. Their skin is usually dark to mimic stones — though an albino, pinkish variety can be bred — and they can stay still for hours, buried in the muddy ground of their natural habitats or barely moving at the bottom of their tanks in captivity.Aside from their lungs, they breathe through their gills and skin, which allows them to adapt to its aquatic environment. And they can regenerate parts of its heart, spinal cord and brain.